Overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy...

SOMERVILLE, Mass.--(BUSINESS WIRE)--Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known...

Ansa’s next-generation enzymatic DNA synthesis technology will dramatically accelerate innovation across every industry enabled by...

Tomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer...

NEW YORK, Jan. 20, 2022 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet...

Amgen wants its future drugs to be multispecific, and so the biopharmaceutical company selected Generate Biomedicines for a $1.9 billion...

Landus farmers will gain access to new carbon revenue stream and digital grain marketing tools AMES, Iowa (December 2, 2021) – Landus,...

Cambridge, Mass, November 18, 2021 – Generate Biomedicines, whose machine learning-powered Generative Biology platform can rapidly invent...

Tessera’s Gene WritingTM Technology is Designed to Simultaneously Correct Multiple Genetic Mutations as well as to Write Genes in Their...